Results 161 to 170 of about 65,986 (255)

Staying in the Unknown: Avoidance of Genetic Testing in Families With Hereditary Cancer Syndromes—A Qualitative Study

Journal of Clinical Nursing, EarlyView.
ABSTRACT Aims To explore the experiences and challenges associated with genetic testing decisions among untested individuals from hereditary breast and ovarian cancer (HBOC) or Lynch syndrome (LS) families. Design Qualitative descriptive study. Methods Semi‐structured telephone interviews were conducted between 2022 and 2024 with 56 untested at‐risk ...
Ronit G. Tsemach, Elizabeth E. Half, Hagit Baris‐Feldman, Anastasia Weis, Sharon Simchoni, Sue Kim, Maria C. Katapodi, Sivia Barnoy, Efrat Dagan   +8 more
wiley   +1 more source

Somatic BRCA alterations in breast cancer are associated with distinct biological and clinical patterns according to germline BRCA status. [PDF]

ESMO Open
Oshi M, Kawashima K, Sugimori M, Yamada A, Shah Z, Onel K, Endo I, Takabe K.   +7 more
europepmc   +1 more source

Identification of a Circular RNA as a Potential Diagnostic and Prognostic Biomarker in Breast Cancer Through Integrated Bioinformatic and Experimental Analyses

Analytical Science Advances, Volume 7, Issue 2, December 2026.
Forty circular RNAs were found to be significantly dysregulated in microarray datasets. Expression levels of hsa_circ_0000231 were significantly upregulated in breast cancer (BC) tissues, while hsa_circ_0011385 exhibited no significant difference in expression levels. This study also revealed that hsa_circ_0000231/hsa‐miR‐5683/CCNB1 regulatory axis may
MohamadReza Hashemi, Pejman Morovat, Azin Khoshghiafeh, Novin Nikbakhsh, Mohamadreza Ahmadifard   +4 more
wiley   +1 more source

The increasing role of breast-conserving treatment in patients with BRCA-related breast cancer: an appraisal of recent literature. [PDF]

Front Oncol
Fancellu A, Giuliani G, Mulas S, Contini AM, Ariu ML, Piredda C, Sanna V.   +6 more
europepmc   +1 more source

An Update on Early‐Onset Breast Cancer: Incidence, Risk Factors, Genetic Testing, and Treatment

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Early‐onset breast cancer presents in patients typically under the age of 40, while very early‐onset breast cancer is usually viewed as breast cancer occurring before the age of 35. Early‐onset breast cancer demonstrates specific molecular properties and has worse outcomes compared to its late‐onset breast cancer counterpart.
Leila Jahangiri
wiley   +1 more source

Real-World Outcomes of Olaparib in Japanese Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of BRCA2 Loss and Microsatellite Instability Status. [PDF]

Int J Urol
Nukaya T, Naiki T, Watanabe H, Nakane K, Inamoto T, Yasui T, Koie T, Takahara K.   +7 more
europepmc   +1 more source

Sex‐Modulated TACSTD2 Methylation and Hormone‐Receptor Axis Interactions in Glioblastoma: Insights Toward Mechanistic Understanding

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
Sex‐stratified analyses of the TCGA and CGGA cohorts have identified promoter‐proximal TACSTD2 CpG sites where methylation shows opposite survival associations in males and females, is independent of copy number, and correlates with TACSTD2 expression.
Tahreem Fatima
wiley   +1 more source

Development and Usability Testing of an Information Needs-Based Chatbot for Individuals With Pathogenic Variants in BRCA Genes in Korea: A Methodological Study. [PDF]

J Genet Couns
Park SY, Kim Y, Katapodi MC, Kim S.
europepmc   +1 more source

HierAnom‐Path: Zero‐Shot Rare Cancer Detection in Histopathology via Hierarchical Foundation Model Adaptation

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Rare cancers collectively represent 20%–25% of all malignancies yet yield fewer than 50 annotated whole‐slide images (WSIs) per subtype in publicly available archives, rendering supervised deep learning inapplicable. We present HierAnom‐Path, to the best of our knowledge, the first framework for zero‐shot rare cancer anomaly detection in ...
Noora Saleem Jumaah, Mohanad Sameer Jabbar, Saif H. Alwaeli, Noor Ayesha, Mohamed Babiker A. Mohamed, Muhammad I. Khan   +5 more
wiley   +1 more source

Factors influencing oncologists' decisions for germline BRCA testing and adjuvant therapy selection in HER2-negative early breast cancer. [PDF]

Front Oncol
Li Q, Cambron-Mellott MJ, Xu X, Kashine-Tack N, Hayes JF, Mishkin KE, Gordon A, Will O, Howell LA, Noval A, Beusterien K.   +10 more
europepmc   +1 more source